Get the Stockscreener App
1.205
1.23%
-0.015
Pmv Pharmaceuticals Inc stock is traded at $1.205, with a volume of 149.05K.
It is down -1.23% in the last 24 hours and up +7.59% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
See More
Previous Close:
$1.22
Open:
$1.235
24h Volume:
149.05K
Relative Volume:
0.40
Market Cap:
$64.26M
Revenue:
-
Net Income/Loss:
$-78.34M
P/E Ratio:
-0.8131
EPS:
-1.4819
Net Cash Flow:
$-75.02M
1W Performance:
-6.59%
1M Performance:
+7.59%
6M Performance:
-1.23%
1Y Performance:
+1.26%
1-Day Range:
$1.20
$1.24
1-Week Range:
$1.195
$1.34
52-Week Range:
$1.02
$1.88
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6670
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.205 | 71.46M | 0 | -78.34M | -75.02M | -1.4819 |
VRTX
Vertex Pharmaceuticals Inc
|
528.23 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.45 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.34 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.28 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
Price to earnings forward of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP - TradingView
Enterprise value to revenue forward of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP - TradingView
Price to book forward of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP - TradingView
Enterprise value to EBIT forward of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP - TradingView
PMV Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PMVP) - TradingView
PMVP Forecast — Price Target — Prediction for 2027 - TradingView
PMV Pharmaceuticals Inc (PMVP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why - Yahoo Finance
PMV Pharmaceuticals Inc (PMVP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PMV Pharmaceuticals Inc (PMVP) Valuation: PE, PB & Fair Value Analysis - TradingKey
PMV Pharmaceuticals Inc (PMVP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PMV Pharmaceuticals Inc (PMVP) Institutional Confidence - TradingKey
PMV Pharmaceuticals Inc (PMVP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PMV Pharmaceuticals Inc (PMVP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PMV Pharmaceuticals Inc (PMVP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PMV Pharmaceuticals Inc (PMVP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PMVP Q1 2026 Earnings: Narrower-Than-Expected Loss Mitigates Stock DeclineEarnings Risk Report - newsline.com
PMVP SEC FilingsPmv Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PMV Pharmaceuticals Stock (US7301281085): Quiet session puts fundamentals and balance sheet in focus - AD HOC NEWS
PMV Pharmaceuticals (PMVP) loses 26% in 4 weeks, here's why a trend reversal may be around the corner - MSN
PMV Pharmaceuticals (PMVP) Q1 2026 Earnings: EPS Beat Driven by Tight Cost Control, Stock Slips on Lack of RevenueEarnings Quality Score - newsline.com
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
PMV Pharmaceuticals Slips Slightly as Shares Approach Critical SupportCounter Trend Trade - newsline.com
PMV Pharmaceuticals (PMVP) Dips 3.5% as Stock Tests Key Support at $1.0Golden Cross - dars.gov.et
PMV Pharmaceuticals (PMVP) grants director 42,000 options at $1.19 - Stock Titan
PMV Pharmaceuticals (PMVP) director receives 42,000 stock options at $1.1900 - Stock Titan
PMV Pharmaceuticals (PMVP) director gifts 84K stock options to trust - Stock Titan
PMV Pharmaceuticals (PMVP) director awarded 42,000 stock options at $1.19 - Stock Titan
Director at PMV Pharmaceuticals (PMVP) granted 42,000 options at $1.19 - Stock Titan
PMV Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results - Minichart
PMV Pharmaceuticals Shareholders Back Directors and Governance Matters - TipRanks
Shareholders back PMV Pharmaceuticals (NASDAQ: PMVP) board, pay plans - Stock Titan
PMVP: Directors elected, compensation and auditor ratified, with no stockholder questions raised - TradingView
PMV Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
PMV Pharmaceuticals Q1 2026 Earnings: EPS Beat Narrows Losses Amid Pre-Revenue Pipeline ProgressEarnings Season Outlook - newsline.com
PMVP Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseNext Quarter Guidance - newsline.com
PMV Pharmaceuticals Advances Cancer Study Amid Adjusted Financial Targets - asatunews.co.id
PMV Pharmaceuticals Advances Cancer Drug Development Amid Financial Adjustments - sekbernews.id
Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity - Insider Monkey
5 Popular Penny Stocks on Robinhood to Watch in 2026 - Insider Monkey
PMVP Q1 2026 Earnings: Narrower Loss Slightly Beats Estimates as Development AdvancesRevenue Miss Report - The Legal Advocate
PMV Pharmaceuticals’ Phase 2 Clinical Trial Progresses; Reports $5 Million in First-Quarter Revenue - geneonline.com
PMV Pharmaceuticals (PMVP) Slips to $1.26 as Cautious Trading Puts Support to the TestCalendar Spread Trade - Newser
PMV Pharmaceuticals, Inc.Common Stock (Nasdaq:PMVP) Stock Quote - FinancialContent
PMV Pharmaceuticals (PMVP) Q1 2026 Earnings Surprise: EPS $-0.34, Up SignificantProfit Cycle Analysis - The Legal Advocate
Number of shareholders of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP - TradingView
Euclidean Capital reports 2.6M shares in PMVP (PMVP) - Stock Titan
PMV Pharmaceuticals (PMVP) Q1 2026 Earnings: Why the Beat MattersShared Trade Ideas - newser.com
PMV Pharmaceuticals (PMVP) price target decreased by 37.50% to 4.84 - MSN
PMVP Maintains Outperform Rating by Oppenheimer -- Price Target Lowered to $5.00 - GuruFocus
Oppenheimer Maintains PMV Pharmaceuticals(PMVP.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pmv Pharmaceuticals Inc Stock (PMVP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Oct 23 '25 |
Sale |
1.52 |
1,000,000 |
1,520,000 |
4,975,291 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):